TY - BOOK ID - 145168988 TI - Proteases—From Basic Structure to Function to Drug Design as Targeted Therapy AU - Kwok, Hang Fai AU - Shaw, Christopher AU - Walker, Brian PY - 2021 PB - Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Research & information: general KW - MMP KW - MMP2 KW - MMP9 KW - MMP7 KW - MMP14 KW - matrix metalloproteases KW - PDAC KW - pancreatic cancer KW - Bowman–Birk inhibitor KW - ranacyclin KW - trypsin inhibitor KW - structure–activity relationship KW - synergistic effect KW - Gentamicin KW - matrix metalloproteinase KW - extracellular matrix KW - nuclei KW - cancer KW - apoptosis KW - immune response KW - cysteine protease inhibitor KW - stefin KW - signal peptide KW - parasite KW - phylogenetic analysis KW - diversification KW - protein structure KW - vascular endothelial growth factors (VEGFs) KW - VEGF-A KW - PlGF KW - VEGF-B KW - VEGF-C KW - VEGF-D KW - angiogenesis KW - lymphangiogenesis KW - CCBE1 KW - proteases KW - ADAMTS3 KW - plasmin KW - cathepsin D KW - KLK3 KW - prostate-specific antigen (PSA) KW - thrombin KW - wound healing KW - metastasis KW - proteolytic activation KW - vascular biology KW - lymphedema KW - MMP KW - MMP2 KW - MMP9 KW - MMP7 KW - MMP14 KW - matrix metalloproteases KW - PDAC KW - pancreatic cancer KW - Bowman–Birk inhibitor KW - ranacyclin KW - trypsin inhibitor KW - structure–activity relationship KW - synergistic effect KW - Gentamicin KW - matrix metalloproteinase KW - extracellular matrix KW - nuclei KW - cancer KW - apoptosis KW - immune response KW - cysteine protease inhibitor KW - stefin KW - signal peptide KW - parasite KW - phylogenetic analysis KW - diversification KW - protein structure KW - vascular endothelial growth factors (VEGFs) KW - VEGF-A KW - PlGF KW - VEGF-B KW - VEGF-C KW - VEGF-D KW - angiogenesis KW - lymphangiogenesis KW - CCBE1 KW - proteases KW - ADAMTS3 KW - plasmin KW - cathepsin D KW - KLK3 KW - prostate-specific antigen (PSA) KW - thrombin KW - wound healing KW - metastasis KW - proteolytic activation KW - vascular biology KW - lymphedema UR - https://www.unicat.be/uniCat?func=search&query=sysid:145168988 AB - In the two last decades, proteases have constituted one of the primary and important targets in drug discovery. The U.S. FDA has approved more than 12 protease therapies in the last 10 years, and a number of next-generation or completely new proteases are under clinical development. Protease inhibition strategies are one of the fastest expanding areas in the field of of drugs that show considerable promise. This Special Issue will focus on the recent advances in the discovery and development of protease inhibitors, covering the synthesis of protease inhibitors, the design of new chemical entities acting as inhibitors of special/particular types of proteases, and their mode of actions (Frolova et al. 2020; Slapak et al. 2020; Künnapuu et al. 2021). In addition, the new applications of these interesting compounds/biomolecules and their limitations have been discussed and described (Wang et al. 2020; Bartošová-Sojková et al. 2021). ER -